623142-96-1

Usage

Uses

1. Used in Pharmaceutical Industry:
N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea is used as a c-fms tyrosine kinase inhibitor for suppressing osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
2. Used in Research Applications:
N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea is used as an inhibitor of macrophage colony stimulating factor 1 (CSF1) receptor tyrosine kinase (c-Fms) in research settings. It inhibits CSF1-dependent c-Fms phosphorylation in a dose-dependent manner in RAW264.7 cells and reduces CSF1-dependent growth of M-NFS-60 cells.
3. Used in Preclinical Models:
N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea is utilized to suppress the development of TRAP-positive osteoclast-like cells from murine bone marrow and decrease the number and area of osteolytic lesions on femurs and tibiae in a murine A375 subcutaneous xenograft model.
4. Used in Arthritis Treatment Research:
In addition to its applications in bone metastasis models, N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea is also used to reduce TNF-α infiltration and osteolytic bone destruction in a collagen-induced arthritis (CIA) mouse model, indicating its potential use in the development of treatments for arthritis and related conditions.

in vitro

ki20227 was found to inhibit c-fms, kdr, c-kit, and platelet-derived growth factor receptor b, but not inhibit other kinases tested, such as epidermal growth factor receptor, fms-like tyrosine kinase-3 , or c-src. ki20227 was also found to inhibit the m-csf dependent growth of m-nfs-60 cells but not the m-csf independent growth of a375 human melanoma cells. furthermore, ki20227 inhibited the development of tartrate-resistant acid phosphatase-positive osteoclast-like cells in a dose-dependent manner [1].

in vivo

oral administration of ki20227 suppressed osteoclast-like cell accumulation and bone resorption induced by metastatic tumor cells in nude rats following intracardiac injection of a375 cells. in addition, ki20227 decreased the number of tartrate-resistant acid phosphatase-positive osteoclast-like cells on bone surfaces in ovariectomized (ovx) rats [1].

references

[1] ohno h, kubo k, murooka h, kobayashi y, nishitoba t, shibuya m, yoneda t, isoe t. a c-fms tyrosine kinase inhibitor, ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. mol cancer ther. 2006;5(11):2634-43.